INBS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Intelligent Bio Solutions Inc (INBS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive developments such as increased manufacturing capacity and expansion plans, the technical indicators suggest a bearish trend, and the company's financial performance shows significant losses with declining EPS and gross margin. Given the lack of strong trading signals and the current market conditions, it is better to hold off on investing in this stock for now.
The stock is in a bearish trend with moving averages showing SMA_200 > SMA_20 > SMA_5. The MACD histogram is negative and contracting, indicating weak momentum. RSI at 6.648 suggests the stock is oversold, but this alone is not enough to warrant a buy. Key support is at 3.893, and resistance is at 5.123.
The company announced a manufacturing partnership with Syrma Johari MedTech, which increased manufacturing capacity by four times and is expected to reduce production costs by over 40%. Intelligent Fingerprinting Drug Screening Readers are being deployed in the U.K. and Europe, and the company is preparing to enter the U.S. market.
The company has a declining EPS (-43.15% YoY) and gross margin (-246.78% YoY). Net income remains negative, indicating ongoing financial struggles. Technical indicators show a bearish trend, and there are no significant trading trends from hedge funds or insiders.
In Q2 2026, revenue increased by 47.62% YoY to $896,774, but net income remains negative at -$2,677,590, albeit improving by 19.03% YoY. EPS dropped significantly by 43.15% YoY to -2.82, and gross margin declined sharply by 246.78% YoY to 19.83%.
No data available for analyst ratings or price target changes.
